Bone Biologics Corp (BBLG) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Bone Biologics Corp (BBLG) stock forecast summary
On Oct. 13, 2026, BBLG is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for BBLG is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BBLG included.
Follow BBLG freeBBLG price chart and AI forecast
How BBLG ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Bone Biologics Corp (BBLG) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
Valuation & Market
| Metric | BBLG | Rank |
|---|---|---|
| EPS | $-1.43 | – |
Profitability & Margins
| Metric | BBLG | Rank |
|---|---|---|
| ROE | -73.7% | 12/20 |
| ROA | -65.2% | 17/20 |
| ROIC | -78.0% | 18/21 |
Financial Health
| Metric | BBLG | Rank |
|---|---|---|
| Current Ratio | 8.67x | 3/24 |
| D/E Ratio | 0.13x | 22/23 |
| Financial Leverage | 1.13x | 22/23 |
| Interest Coverage | -3543.3x | 21/21 |
| Working Capital | $4M | 19/22 |
Cash Flow
| Metric | BBLG | Rank |
|---|---|---|
| Operating Cash Flow | -$3M | 14/22 |
Income Statement
| Metric | BBLG | Rank |
|---|---|---|
| Operating Income | -$3M | 10/22 |
| Net Income | -$2M | 8/18 |
| R&D Expense | $900K | 16/19 |
Dividend & Shareholder Information
| Metric | BBLG | Rank |
|---|---|---|
| EPS Growth | -314.2% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4M | |
| Cash & Short-term Investments | $4M | |
| Total Liabilities | $510K | |
| Short-term Debt | $0.00M |
BBLG quarterly financials and insider trading
Bone Biologics Corp (BBLG) industry peers
Companies classified under the same SEC industry code as Bone Biologics Corp (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BBLG Bone Biologics Corp | ▶ | N/A |
| ISRG Intuitive Surgical Inc | ▼ | $149.10B |
| SNN Smith & Nephew Plc | ▼ | $24.29B |
| STE Steris Plc | ▼ | $21.35B |
| ZBH Zimmer Biomet Holdings, Inc. | ▼ | $17.58B |
| ALGN Align Technology Inc | ▼ | $10.20B |
| MSA Msa Safety Inc | ▼ | $7.01B |
| ESTA Establishment Labs Holdings Inc. | ▲ | $1.74B |
| CDRE Cadre Holdings, Inc. | ▶ | $1.12B |
| ENOV Enovis Corp | ▶ | $1.10B |
| AVR Anteris Technologies Global Corp. | ▼ | $629M |
| SMTI Sanara Medtech Inc. | ▼ | $323M |
| INGN Inogen Inc | ▶ | $168M |
| LAKE Lakeland Industries Inc | ▲ | $97M |
| NTRB Nutriband Inc. | ▲ | $71M |
| APT Alpha Pro Tech Ltd | ▲ | $59M |
| MYO Myomo, Inc. | ▲ | $51M |
| COCH Envoy Medical, Inc. | ▶ | $50M |
| MLSS Milestone Scientific Inc. | ▲ | $31M |
| LFWD Lifeward Ltd. | ▲ | $18M |
| UEEC United Health Products, Inc. | ▶ | $12M |
| RGNT Regentis Biomaterials Ltd. | ▼ | $8M |
| CLGN Collplant Biotechnologies Ltd | ▶ | $5M |
| RBOT Vicarious Surgical Inc. | ▼ | $360K |
| FEED Envue Medical, Inc. | ▼ | $320K |
| CUPR Cuprina Holdings (Cayman) Ltd | ▼ | N/A |
| LGMK Logicmark, Inc. | ▼ | N/A |
Where BBLG sits on the market map
Bone Biologics Corp (BBLG) stock news
Loading...
Bone Biologics Corp (BBLG) stock forecast FAQ
What is the Bone Biologics Corp (BBLG) stock forecast?
On Oct. 13, 2026, BBLG is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Bone Biologics Corp stock predictions?
A per-ticker accuracy statistic for BBLG is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Bone Biologics Corp forecasts updated?
Bone Biologics Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Bone Biologics Corp's industry peers?
27 issuers in our coverage, BBLG included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Smith & Nephew Plc (SNN), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Align Technology Inc (ALGN), Msa Safety Inc (MSA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.